GU
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EMBARK Study Post-Hoc Analysis By Age - Enzalutamide +/- Leuprolide in Patients With High-Risk Biochemically Recurrent Prostate Cancer
FEATURING
Neal Shore
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and AMBASSADOR (MIUC)
FEATURING
Elizabeth R. Plimack
- 10 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment
FEATURING
Guru Sonpavde
- 43 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)
FEATURING
Robert Dreicer
- 45 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC
FEATURING
Félix Guerrero-Ramos
- 24 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4
FEATURING
Bogdana Schmidt
- 12 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR
FEATURING
Petros Grivas
- 141 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan vs. Everolimus in Patients With Previously Treated Advanced ccRCC
FEATURING
Brian Rini
- 19 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: RAPSON Study - Radium223-Docetaxel vs. Docetaxel-Radium223 Sequence in mCRPC with Prospective Biomarker Evaluation
FEATURING
Vincenza Conteduca
- 1 view
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Comparison P - Upfront Accelerated 177Lu-PSMA-617 in mHSPC
FEATURING
Minal Padden-Modi,
Nick James
- 3 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation vs. Placebo in Patients Receiving Pembro + Axitinib for mRCC
FEATURING
Chiara Ciccarese
- 15 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT
FEATURING
Hoda Abdel-Aty
- 11 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PEACE-1 Trial - Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer
FEATURING
Cedric Pobel
- 3 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: VOLGA Trial - ctDNA Clearance in Cisplatin-Ineligible MIBC With Durvalumab + Tremelimumab + Enfortumab Vedotin
FEATURING
Alexandra Drakaki
- 21 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SOGUG-AUREA Study - Split-Dose Cisplatin and Atezolizumab in Cisplatin-Ineligible Urothelial Carcinoma
FEATURING
Guillermo de Velasco
- 24 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Predictive Tumor Suppressor Gene Signature for Early Progression in mHSPC
FEATURING
Marta Garcia De Herreros
- 6 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC - Ph3 CheckMate 67T
FEATURING
Laurence Albiges
- 70 views
- September 19, 2024